These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 9334364)

  • 1. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity.
    Song W; Kong HL; Carpenter H; Torii H; Granstein R; Rafii S; Moore MA; Crystal RG
    J Exp Med; 1997 Oct; 186(8):1247-56. PubMed ID: 9334364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases.
    Specht JM; Wang G; Do MT; Lam JS; Royal RE; Reeves ME; Rosenberg SA; Hwu P
    J Exp Med; 1997 Oct; 186(8):1213-21. PubMed ID: 9334360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
    J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.
    Kikuchi T; Moore MA; Crystal RG
    Blood; 2000 Jul; 96(1):91-9. PubMed ID: 10891436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
    Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
    J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T; Miyazawa N; Moore MA; Crystal RG
    Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.
    Okada N; Masunaga Y; Okada Y; Mizuguchi H; Iiyama S; Mori N; Sasaki A; Nakagawa S; Mayumi T; Hayakawa T; Fujita T; Yamamoto A
    Gene Ther; 2003 Oct; 10(22):1891-902. PubMed ID: 14502218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity.
    Kianmanesh A; Hackett NR; Lee JM; Kikuchi T; Korst RJ; Crystal RG
    Hum Gene Ther; 2001 Nov; 12(17):2035-49. PubMed ID: 11747595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
    Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
    Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.
    Kim KD; Choi SC; Kim A; Choe YK; Choe IS; Lim JS
    Int Immunopharmacol; 2001 Nov; 1(12):2117-29. PubMed ID: 11710541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor.
    Broder H; Anderson A; Odesa SK; Kremen TJ; Liau LM
    Neurosurg Focus; 2000 Dec; 9(6):e6. PubMed ID: 16817689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor.
    Broder H; Anderson A; Kremen TJ; Odesa SK; Liau LM
    J Neurooncol; 2003; 64(1-2):21-30. PubMed ID: 12952283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and in vitro modulation of immune stimulatory capacity of primary dendritic cells by adenovirus-mediated gene transduction.
    Sonderbye L; Feng S; Yacoubian S; Buehler H; Ahsan N; Mulligan R; Langhoff E
    Exp Clin Immunogenet; 1998; 15(2):100-11. PubMed ID: 9691204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas.
    Melero I; Duarte M; Ruiz J; Sangro B; Galofré J; Mazzolini G; Bustos M; Qian C; Prieto J
    Gene Ther; 1999 Oct; 6(10):1779-84. PubMed ID: 10516729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells.
    Schnell S; Young JW; Houghton AN; Sadelain M
    J Immunol; 2000 Feb; 164(3):1243-50. PubMed ID: 10640737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.
    Worgall S; Busch A; Rivara M; Bonnyay D; Leopold PL; Merritt R; Hackett NR; Rovelink PW; Bruder JT; Wickham TJ; Kovesdi I; Crystal RG
    J Virol; 2004 Mar; 78(5):2572-80. PubMed ID: 14963160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of antigen-specific cytotoxic T lymphocytes by beta 2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic embryonic stem cell-derived dendritic cells.
    Matsunaga Y; Fukuma D; Hirata S; Fukushima S; Haruta M; Ikeda T; Negishi I; Nishimura Y; Senju S
    J Immunol; 2008 Nov; 181(9):6635-43. PubMed ID: 18941254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.